Xeris Biopharma Holdings (XERS) Goodwill (2021 - 2026)

Xeris Biopharma Holdings' Goodwill history runs 6 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• Quarterly Goodwill changed 0.0% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.9 million (changed 0.0% YoY) and the FY2025 annual result came in at $22.9 million, changed 0.0% from the prior year.
• Goodwill was $22.9 million for Q1 2026 at Xeris Biopharma Holdings, roughly flat from $22.9 million in the prior quarter.
• Across five years, Goodwill topped out at $22.9 million in Q1 2022 and bottomed at $22.9 million in Q1 2022.
• A 5-year average of $22.9 million and a median of $22.9 million in 2022 frame the typical range for Goodwill.
• Peak annual rise in Goodwill reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Xeris Biopharma Holdings' Goodwill stood at $22.9 million in 2022, then changed by 0.0% to $22.9 million in 2023, then changed by 0.0% to $22.9 million in 2024, then changed by 0.0% to $22.9 million in 2025, then changed by 0.0% to $22.9 million in 2026.
• Business Quant data shows XERS's Goodwill at $22.9 million in Q1 2026, $22.9 million in Q4 2025, and $22.9 million in Q3 2025.